Agents like mazdutide, survodutide, and pemvidutide pair GLP-1 with glucagon receptor activity, targeting both obesity and metabolic dysfunction‐associated steatohepatitis (MASH). Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.